Icon Plc $ICLR Shares Acquired by Capital International Ltd. CA

Capital International Ltd. CA grew its stake in Icon Plc (NASDAQ:ICLR) by 569.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,246 shares of the medical research company’s stock after purchasing an additional 24,875 shares during the quarter. Capital International Ltd. CA’s holdings in Icon were worth $5,329,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Muhlenkamp & Co. Inc. acquired a new stake in shares of Icon in the third quarter valued at about $12,857,000. Mitchell Capital Management Co. acquired a new position in Icon during the third quarter worth about $1,627,000. First National Bank of Omaha acquired a new position in Icon during the third quarter worth about $6,267,000. Allspring Global Investments Holdings LLC boosted its position in Icon by 1.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,080,192 shares of the medical research company’s stock worth $203,800,000 after acquiring an additional 11,335 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Icon during the third quarter worth about $39,074,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Stock Performance

NASDAQ:ICLR opened at $149.45 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.10 and a quick ratio of 1.10. The firm has a market capitalization of $12.07 billion, a price-to-earnings ratio of 24.26, a PEG ratio of 10.13 and a beta of 1.26. The company’s 50-day moving average is $117.51 and its two-hundred day moving average is $140.85. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share for the quarter. The company had revenue of $2.11 billion for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Analysts forecast that Icon Plc will post 9.74 EPS for the current year.

Analyst Ratings Changes

ICLR has been the topic of a number of recent research reports. Zacks Research lowered shares of Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. boosted their price target on shares of Icon from $120.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, May 29th. Bank of America restated an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Jefferies Financial Group restated a “buy” rating and set a $165.00 price target on shares of Icon in a research report on Friday, May 29th. Finally, TD Cowen boosted their price target on shares of Icon from $120.00 to $164.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Icon presently has an average rating of “Hold” and a consensus target price of $156.44.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.